Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

NCT07263360 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

BTC

Interventions

DRUG: Iparomlimab and Tuvonralimab Injection combined with GemOX and lenvatinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital